We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Is Expanded Mutation Testing Practical for CF Carrier Screening?

By LabMedica International staff writers
Posted on 06 Dec 2010
A new study questioned the value of expanded genetic testing for cystic fibrosis.

The findings suggested that expanded panels might promote ill-informed decisions and anxiety for physicians and couples seeking testing to determine their risk of passing the disease to their children.

Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to an eight-year study performed by scientists at Quest Diagnostics (Madison, NJ, USA). More...


Participants in the study came from an ethnically diverse American population. It involved analyses of more than three million deidentified test results performed by the company's laboratories over an eight-year period ending in April 2010.

The company's scientists found that CF testing, using 23 recommended mutations plus an additional eight to nine clinically validated mutations performed for patients in its labs, identified nearly 100 % of carriers among Caucasians, including Ashkenazi Jews, the highest risk group for CF, as compared to well-established estimated carrier rates. The CF testing also performed comparably to the American College of Obstetricians and Gynecologists (ACOG; Washington DC, USA) predictions for performance in detecting carriers in African, Hispanic, and Asian Americans.

In 2004, the American College of Medical Genetics (ACMG; Bethesda, MD, USA) and ACOG recommended physicians offer panels based on the 23 recommended mutations to couples to help identify carrier status. Despite the guidelines, expanded test panels that identify dozens up to nearly 100 nonguideline recommended mutations are widely offered by certain laboratories in the US.

The study findings appear online in the journal Genetics in Medicine.

"This outstanding study should finally put to rest the continuing debates and misinformation that suggest more mutations are always better when it comes to cystic fibrosis carrier screening," said Wayne W. Grody, MD, PhD, professor in the departments of pathology and laboratory medicine, pediatrics, and Human Genetics at the UCLA School of Medicine (Los Angeles, CA, USA). Dr. Grody led one of the influential NIH-funded pilot studies on CF carrier screening and cochaired the ACMG committee that developed the recommended core mutation-screening panel. He is not affiliated with the study or with Quest Diagnostics.

Related Links:
Quest Diagnostics
American College of Obstetricians and Gynecologists
American College of Medical Genetics
UCLA School of Medicine


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.